GlassScriptPhysician profile
Taylor Slagter
NPI 1427650530
$1,684.11
in general payments reported to CMS, 2019-2025
21 companies · $707 in 2025
The $707 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.04 · 2022: $202 · 2023: $341 · 2024: $423 · 2025: $707.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,471.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,470.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $474.96 | 2022-2025 | Ofev, Stiolto Respimat |
| Regeneron Healthcare Solutions, INC. | $225.95 | 2024-2025 | Dupixent |
| Glaxosmithkline, LLC. | $140.10 | 2022-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Actelion Pharmaceuticals US, INC. | $135.53 | 2022-2024 | Opsumit, Uptravi |
| Genzyme Corporation | $96.86 | 2025 | |
| United Therapeutics Corporation | $77.59 | 2024-2025 | Tyvaso, Tyvaso |
| Grifols USA, LLC | $67.57 | 2024-2025 | Prolastin-C Liquid |
| Harmony Biosciences LLC | $59.30 | 2023-2025 | Wakix |
| Astrazeneca Pharmaceuticals LP | $52.64 | 2024-2025 | Fasenra, Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $51.98 | 2023-2024 | Glassia |
| Electromed, INC. | $48.39 | 2024-2025 | Smartvest |
| Pulmonx Corporation | $45.62 | 2024-2025 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Medtronic, INC. | $37.39 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $33.27 | 2023 | Purified Cortrophin Gel |
| Insmed, INC. | $28.23 | 2025 | Brinsupri, Arikayce |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $26.12 | 2025 | Winrevair |
| Inspire Medical Systems, INC. | $19.19 | 2025 | Inspire |
| Mallinckrodt Hospital Products INC. | $18.21 | 2025 | Acthar |
| Paratek Pharmaceuticals, INC. | $16.12 | 2025 | Nuzyra |
| Lilly USA, LLC | $15.10 | 2025 | Zepbound |
| Viatris Specialty LLC | $13.99 | 2025 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Slagter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.